Evaxion - EBIT 2020-2025 | EVAX
Evaxion - ebit from 2020 to 2025. Ebit can be defined as earnings before interest and taxes.
| Evaxion - Annual EBIT (Millions of US $) |
|
|---|---|
| 2024 | $-15 |
| 2023 | $-22 |
| 2022 | $-25 |
| 2021 | $-26 |
| 2020 | $-17 |
| 2019 | $-11 |
| Evaxion - Quarterly EBIT (Millions of US $) |
|
|---|---|
| 2025-03-31 | $-4 |
| 2024-06-30 | $-5 |
| 2023-06-30 | $-6 |
| 2022-06-30 | $-6 |
| 2022-03-31 | $-6 |
| 2021-12-31 | $-8 |
| 2021-09-30 | $-6 |
| 2021-06-30 | $-7 |
| 2021-03-31 | $-5 |
| 2020-12-31 | $-5 |
| 2020-09-30 | $-5 |
| 2020-06-30 | $-4 |
| 2020-03-31 | $-3 |
| 2019-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.004B | $0.003B |
| Evaxion A/S is a clinical-stage TechBio company specializing in developing AI-Immunology(TM) powered vaccines. Evaxion A/S, formerly known as Evaxion Biotech A/S, is based in COPENHAGEN, Denmark. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $47.456B | 60.38 |
| Hims & Hers Health (HIMS) | United States | $12.904B | 134.07 |
| Doximity (DOCS) | United States | $11.414B | 52.84 |
| Tempus AI (TEM) | United States | $11.164B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.284B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.801B | 59.38 |
| Hinge Health (HNGE) | United States | $3.571B | 0.00 |
| Privia Health (PRVA) | United States | $2.402B | 164.21 |
| 10x Genomics (TXG) | United States | $1.737B | 0.00 |
| Schrodinger (SDGR) | United States | $1.631B | 0.00 |
| Phreesia (PHR) | United States | $1.585B | 0.00 |
| Azenta (AZTA) | United States | $1.576B | 73.26 |
| Enovis (ENOV) | United States | $1.573B | 8.77 |
| Clover Health Investments (CLOV) | United States | $1.545B | 0.00 |
| Omnicell (OMCL) | United States | $1.324B | 23.36 |
| Evolent Health (EVH) | United States | $1.166B | 99.30 |
| Claritev (CTEV) | United States | $0.652B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.559B | 0.00 |
| Standard BioTools (LAB) | United States | $0.532B | 0.00 |
| Veradigm (MDRX) | United States | $0.503B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.487B | 0.00 |
| Talkspace (TALK) | United States | $0.421B | 125.75 |
| TruBridge (TBRG) | United States | $0.353B | 783.33 |
| Outset Medical (OM) | United States | $0.328B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.270B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.258B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.240B | 0.00 |
| CapsoVision (CV) | United States | $0.185B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.161B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.160B | 0.00 |
| American Well (AMWL) | United States | $0.140B | 0.00 |
| Pulmonx (LUNG) | United States | $0.134B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.118B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.118B | 0.00 |
| CareCloud (CCLD) | United States | $0.104B | 3.95 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.099B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.083B | 0.00 |
| 111 (YI) | China | $0.063B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.052B | 0.00 |
| HeartBeam (BEAT) | United States | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.026B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.022B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.000B | 0.00 |